NM
NMTC.US Neuroone Medical Technologies Corp
- Market cap
- USD 6.78M
- P/E
- -
- P/B
- 1.80x
- ROE
- -195.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is NMTC.US undervalued?
Graham numberThe Graham number of Neuroone Medical Technologies Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neuroone Medical Technologies Corp fundamental analysis
No fundamental analysis for Neuroone Medical Technologies Corp yet.
Neuroone Medical Technologies Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neuroone Medical Technologies Corp
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surg…
Full company profileNeuroone Medical Technologies Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neuroone Medical Technologies Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 742.00 | 0.00 | 0.00 | 0.00 | 1.93M | 178K | 171K | 1.95M | 3.45M | 12.1M | 9.68M |
| Gross Profit | 742.00 | -7.74K | -21.7K | -27.6K | 1.86M | -97.7K | -70.8K | 457K | 1.08M | 8.14M | 5.38M |
| Operating Income | -30.9K | -32.6K | -3.21M | -5.81M | -4.90M | -10.2M | -10.0M | -12.0M | -11.9M | -4.23M | -8.31M |
| EBITDA | -30.9K | -15.0K | -4.14M | -5.79M | -4.85M | -9.86M | -9.88M | -11.7M | -11.8M | -3.01M | -7.14M |
| Net Income | -62.9K | -47.8K | -6.83M | -6.78M | -13.6M | -9.95M | -10.00M | -11.9M | -12.3M | -3.61M | -7.37M |
| EPS | -0.04 | -0.17 | -15 | -10 | -15 | -5.58 | -3.75 | -3.93 | -2.76 | -0.54 | -0.84 |
| Balance Sheet | |||||||||||
| Total Assets | 1.84K | 757K | 219K | 533K | 4.76M | 7.94M | 12.8M | 8.10M | 5.37M | 10.8M | 6.19M |
| Total Liabilities | 83.3K | 1.02M | 4.61M | 1.77M | 2.69M | 1.38M | 3.22M | 1.85M | 4.55M | 3.71M | 2.42M |
| Shareholders' Equity | -81.5K | -266K | -4.40M | -1.24M | 2.07M | 6.55M | 9.60M | 6.25M | 822K | 7.07M | 3.77M |
| Cash & Short-term Investments | -1.84K | 522K | 13.3K | 261K | 4.04M | 6.90M | 11.1M | 5.32M | 1.46M | 6.57M | 2.05M |
| Total Debt | 13.6K | 275K | 1.68M | - | 1.32M | 316K | 203K | 184K | 260K | 267K | 73.3K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -30.2K | -21.1K | -2.83M | -5.40M | -3.43M | -8.60M | -7.52M | -12.9M | -11.0M | -2.84M | -7.37M |
| Capital Expenditure | 58.4K | 91.7K | 91.7K | 123K | 122K | 67.1K | 275K | 384K | 120K | 81.7K | 132K |
| Free Cash Flow | -30.2K | -21.1K | -2.83M | -5.52M | -3.55M | -8.67M | -7.79M | -13.3M | -11.1M | -2.92M | -7.50M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -660.2% | -151.8% | -104.1% | -189.8% | -1,498.5% | -51.0% | -195.7% |
| ROA | -3,420.2% | -6.3% | -3,121.3% | -1,273.2% | -286.6% | -125.3% | -78.0% | -146.5% | -229.4% | -33.4% | -119.2% |
| Net Profit Margin | -8,472.1% | - | - | - | -708.0% | -5,584.3% | -5,842.0% | -607.4% | -356.7% | -29.8% | -76.2% |
| Debt to Equity | - | - | - | - | 0.64x | 0.05x | 0.02x | 0.03x | 0.32x | 0.04x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neuroone Medical Technologies Corp dividends
Neuroone Medical Technologies Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:6 on Apr 16, 2026.
Who owns Neuroone Medical Technologies Corp
- Insiders 25.54%
- Institutions 17.49%
- Public & others 56.98%
- Shares outstanding 9.11M
- Free float 6.26M
Top funds holding NMTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 255K | 2.80% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 44.6K | 0.49% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 21.5K | 0.24% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 13.9K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 11.9K | 0.13% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 7.09K | 0.08% | -8.09% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 4.66K | 0.05% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 1.48K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding NMTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bleichroeder LP | 667K | 7.32% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 353K | 3.87% | +51.47% | Jun 2026 |
| Bard Associates Inc | 305K | 3.35% | -0.43% | Jun 2026 |
| Perkins Capital Management Inc | 245K | 2.69% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 93.6K | 1.03% | -8.82% | Jun 2026 |
| Sio Capital Management, LLC | 82.8K | 0.91% | 0.00% | Jun 2026 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 57.0K | 0.63% | +99.99% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 49.0K | 0.54% | +0.69% | Jun 2026 |
| Essex Investment Management Company, LLC | 43.6K | 0.48% | -0.19% | Jun 2026 |
| BlackRock Inc | 25.1K | 0.28% | 0.00% | Jun 2026 |
| Northern Trust Corp | 21.4K | 0.24% | +14.50% | Jun 2026 |
| Citadel Advisors Llc | 15.0K | 0.17% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 13.5K | 0.15% | 0.00% | Jun 2026 |
| Belpointe Asset Management LLC | 12.5K | 0.14% | 0.00% | Jun 2026 |
| Legato Capital Management LLC | 10.3K | 0.11% | -0.01% | Jun 2026 |
| UBS Group AG | 2.62K | 0.03% | +14,472.22% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.06K | 0.02% | +2.08% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 361.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 166.00 | 0.00% | -0.60% | Jun 2026 |
| Tower Research Capital LLC | 112.00 | 0.00% | 0.00% | Jun 2026 |
Neuroone Medical Technologies Corp company profile
- Company name
- Neuroone Medical Technologies Corp
- Ticker
- NMTC.US
- Exchange
- USA Stocks
- Listed since
- Sep 18, 2017
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 18
- Fiscal year end
- September
- Address
- 7599 Anagram Drive, Eden Prairie, MN, United States, 55344
- Phone
- 952 426 1383
- Website
- nmtc1.com
About Neuroone Medical Technologies Corp
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.
Neuroone Medical Technologies Corp management
9- Mr. David A. Rosa M.D.President, CEO & Director · born 1964
- Mr. Christopher R. Volker CFAChief Financial Officer
- Mr. Ronald W. McClurgSenior Advisor · born 1958
- Mr. Mark ChristiansonCo-Founder, Business Development Director & Medical Sales Liaison · born 1967
- Mr. Steven MertensChief Technology Officer · born 1963
- Ms. Emily JohnsChief Administrative Officer & General Counsel · born 1991
- Mr. Hijaz HarisVice President of Marketing
- Dr. Parag G. Patil M.D., Ph.D.Chief Medical Advisor
- Mr. David J. WambeckeChief Business Officer · born 1984